On April 15, 2024. Broadwood Capital, Inc. announced that, it have been, and may continue to be, in contact with members of the OncoCyte Corporation management, the board of directors of the Company, other significant shareholders and others regarding alternatives that the Company could employ to maximize the creation of shareholder value over time.